Comparison 9. OLANZAPINE versus RISPERIDONE - sensitivity analysis (skewed data excluded).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1. General - average endpoint score (PANSS total, high=poor)	14	2348	Mean Difference (IV, Random, 95% CI)	−1.99 [−3.37,−0.60]
1.1 short term	6	686	Mean Difference (IV, Random, 95% CI)	−1.02 [−3.15, 1.11]
1.2 medium term	3	231	Mean Difference (IV, Random, 95% CI)	−4.11 [−8.93, 0.71]
1.3 long term	5	1431	Mean Difference (IV, Random, 95% CI)	−2.59 [−4.98, −0.20]
2 Mental state: 2. General - average endpoint score - long term (BPRS total, high=poor)	2	393	Mean Difference (IV, Random, 95% CI)	−4.28 [−9.91, 1.34]
3 Mental state: 3. Positive symptoms - average endpoint score (PANSS positive, high=poor)	12	1663	Mean Difference (IV, Random, 95% CI)	−0.62 [−1.21, −0.03]
3.1 short term	4	622	Mean Difference (IV, Random, 95% CI)	0.28 [−1.07, 1.62]
3.2 medium term	3	231	Mean Difference (IV, Random, 95% CI)	−1.58 [−3.20, 0.03]
3.3 long term	5	810	Mean Difference (IV, Random, 95% CI)	−0.68 [−1.40, 0.04]
4 Adverse effects: 1. Extrapyramidal symptoms - scale measured	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 dyskinesia: ESRS subscore for dyskinesia (high=poor)	2	401	Mean Difference (IV, Random, 95% CI)	−0.10 [−0.62, 0.42]
4.2 extrapyramidal symptoms: ESRS total score (high=poor)	2	530	Mean Difference (IV, Random, 95% CI)	−0.16 [−0.90, 0.58]
4.3 extrapyramidal symptoms: Simpson-Angus Scale (high=poor)	4	487	Mean Difference (IV, Random, 95% CI)	−0.75 [−1.59, 0.10]
4.4 parkinsonism: ESRS subscore for parkinsonism (high=poor)	2	401	Mean Difference (IV, Random, 95% CI)	−1.06 [−3.42, 1.31]
5 Adverse effects: 2. Prolactin - change from baseline in ng/ml	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 Change from baseline in ng/ml	5	1256	Mean Difference (IV, Random, 95% CI)	−24.70 [−28.33, −21. 08]